AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
AnaptysBio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
AnaptysBio's revenue for the twelve months ending Jun 30, 2026 was $237.61M, up 92.9% year over year. For fiscal 2025 it was $234.60M, up 157.0% from the year before. Over ten years it grew 29.6% a year on average. The highest annual figure on record is $234.60M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $234.60M | +157.0% |
| FY2024 | Dec 31, 2024 | $91.28M | +432.0% |
| FY2023 | Dec 31, 2023 | $17.16M | +66.8% |
| FY2022 | Dec 31, 2022 | $10.29M | -83.7% |
| FY2021 | Dec 31, 2021 | $63.18M | -15.8% |
| FY2020 | Dec 31, 2020 | $75.00M | +837.5% |
| FY2019 | Dec 31, 2019 | $8.00M | +60.0% |
| FY2018 | Dec 31, 2018 | $5.00M | -50.0% |
| FY2017 | Dec 31, 2017 | $10.00M | -40.1% |
| FY2016 | Dec 31, 2016 | $16.68M | -5.0% |
| FY2015 | Dec 31, 2015 | $17.57M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $27.49M | +23.5% |
| Q1 FY2026 | Mar 31, 2026 | $25.56M | -8.0% |
| Q4 FY2025 | Dec 31, 2025 | $108.25M | +151.1% |
| Q3 FY2025 | Sep 30, 2025 | $76.32M | +154.3% |
| Q2 FY2025 | Jun 30, 2025 | $22.26M | +102.9% |
| Q1 FY2025 | Mar 31, 2025 | $27.77M | +286.8% |
| Q4 FY2024 | Dec 31, 2024 | $43.11M | +378.8% |
| Q3 FY2024 | Sep 30, 2024 | $30.02M | +804.7% |
| Q2 FY2024 | Jun 30, 2024 | $10.97M | +217.1% |
| Q1 FY2024 | Mar 31, 2024 | $7.18M | +422.5% |
| Q4 FY2023 | Dec 31, 2023 | $9.01M | +32.3% |
| Q3 FY2023 | Sep 30, 2023 | $3.32M | +156.6% |
| Q2 FY2023 | Jun 30, 2023 | $3.46M | +184.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.37M | +41.6% |
| Q4 FY2022 | Dec 31, 2022 | $6.81M | +573.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.29M | -93.8% |
| Q2 FY2022 | Jun 30, 2022 | $1.22M | -96.0% |
| Q1 FY2022 | Mar 31, 2022 | $970.00K | -91.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.01M | -98.3% |
| Q3 FY2021 | Sep 30, 2021 | $20.89M | – |
| Q2 FY2021 | Jun 30, 2021 | $30.03M | – |
| Q1 FY2021 | Mar 31, 2021 | $11.25M | -25.0% |
| Q4 FY2020 | Dec 31, 2020 | $60.00M | +1900.0% |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | -100.0% |
| Q1 FY2020 | Mar 31, 2020 | $15.00M | – |
| Q4 FY2019 | Dec 31, 2019 | $3.00M | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | -100.0% |
| Q2 FY2019 | Jun 30, 2019 | $5.00M | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | -100.0% |
| Q3 FY2018 | Sep 30, 2018 | $5.00M | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | -100.0% |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $3.00M | +8.9% |
| Q3 FY2017 | Sep 30, 2017 | $0 | -100.0% |
| Q2 FY2017 | Jun 30, 2017 | $7.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
| Q4 FY2016 | Dec 31, 2016 | $2.75M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.21M | – |
See a number that looks wrong?